Why Moderna Inc (MRNA) Stock Is Rising
As of 2026-11-12, Moderna Inc (MRNA) has a next-year EPS growth estimate of 43.08%. Featured in 6 EPS revision reports, most recently on 2026-10-15.
Why MRNA Stock Is Rising
- +EPS Estimate Upgraded: Analysts raised Moderna Inc's next-year EPS growth estimate from 43.52% to 45.53% on 2026-11-06.
- ·Current-Year Growth: Projected at -3.68%, supporting the forward estimate revision.
News Context
The primary structural driver is the Nov. 6 analyst upgrade to MRNA’s next-year EPS growth estimate, from 43.52% to 45.53% (+2.01 pp), now at 43.78%. That revision aligns with Q3 results showing an earnings beat, a swing to profit, COVID vaccine sales strength, and a raised 2026 sales outlook. Headlines also show the stock reaching 52-week and multi-year highs after earnings, indicating momentum continued beyond the initial estimate change.
Generated 2026-11-11 · news as of 2026-11-10
Current Snapshot
- Sector
- Healthcare
- Industry
- Biotechnology
- EPS growth next year
- 43.08%
- EPS growth this year
- -3.68%
- EPS next quarter (est)
- -$2.07
- Last price
- $231.35
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-11-12 | 43.08% | -3.68% | -$2.07 | $231.35 |
| 2026-11-11 | 43.62% | -6.14% | -$2.07 | $248.69 |
| 2026-11-10 | 43.78% | -6.80% | -$2.01 | $250.83 |
| 2026-11-09 | 44.21% | -7.62% | -$2.01 | $269.00 |
| 2026-11-07 | 45.53% | -12.12% | -$1.98 | $254.19 |
| 2026-11-06 | 45.53% | -12.12% | -$1.98 | $254.19 |
| 2026-11-05 | 43.52% | -15.96% | -$1.10 | $241.46 |
| 2026-11-04 | 43.52% | -15.96% | -$1.10 | $258.38 |
| 2026-11-03 | 43.52% | -15.96% | -$1.10 | $228.44 |
| 2026-11-02 | 43.52% | -15.96% | -$1.10 | $220.83 |
| 2026-10-31 | 43.52% | -15.96% | -$1.10 | $221.72 |
| 2026-10-30 | 43.52% | -15.96% | -$1.10 | $221.72 |
| 2026-10-29 | 43.52% | -15.96% | -$1.10 | $222.76 |
| 2026-10-28 | 43.53% | -15.98% | -$1.11 | $214.16 |
| 2026-10-27 | 43.53% | -15.98% | -$1.11 | $207.97 |
| 2026-10-26 | 43.53% | -15.98% | -$1.11 | $198.85 |
| 2026-10-23 | 43.37% | -15.98% | -$1.11 | $200.10 |
| 2026-10-22 | 43.37% | -15.98% | -$1.11 | $202.63 |
| 2026-10-21 | 42.92% | -14.64% | -$1.07 | $245.81 |
| 2026-10-20 | 42.64% | -14.68% | -$1.09 | $242.08 |
| 2026-10-19 | 42.64% | -14.68% | -$1.09 | $226.89 |
| 2026-10-16 | 43.00% | -14.49% | -$1.09 | $218.01 |
| 2026-10-15 | 43.00% | -14.49% | -$1.09 | $236.50 |
| 2026-10-14 | 43.02% | -14.57% | -$1.10 | $226.30 |
| 2026-10-13 | 43.02% | -14.57% | -$1.10 | $216.25 |
| 2026-10-12 | 43.02% | -14.57% | -$1.10 | $213.74 |
| 2026-10-11 | 43.02% | -14.57% | -$1.10 | $225.00 |
| 2026-10-10 | 43.02% | -14.57% | -$1.10 | $225.00 |
| 2026-10-09 | 43.02% | -14.57% | -$1.10 | $225.00 |
| 2026-10-08 | 42.92% | -14.57% | -$1.10 | $197.00 |
Reports Featuring MRNA
- 2026-10-15
MRNA Jumps 20.1% on EPS Revision and Goldman Upgrade; VRA, WQEY, RGEN Surge
- 2026-10-14
MRNA Jumps 14.9%, NVAX Up 12.7% as Healthcare Stocks Ride EPS Revisions
- 2026-07-07
WBX +40.8% Leads EPS Revision Winners; NMAX Surges on 217.8pp EPS Upgrade
- 2026-07-06
Stock Surge Alert: WBX +47%, IOT +29%, MRNA +22% on EPS Revisions
- 2026-07-02
Top Stock Gainers Driven by EPS Estimate Revisions: QNRX Up 40.9%, IOT Up 24% - July 2, 2026
- 2026-07-01
Top EPS Revision-Driven Movers: QNRX Surges +44.9% as NMAX Sees 376.9% Growth Estimate
Recent News
- Moderna (MRNA) Stock Hits 52-Week Highs After Q3 Earnings: Buy, Hold, or Sell?Zacks
- Moderna earnings analysis: questions answered and next catalystsInvesting.com
- Moderna Hits Five-Year High On Sales Beat; But The Real Story Is Still Its Cancer VaccineInvestor's Business Daily
- Earnings live updates: Moderna's COVID vaccine sales drive revenue growth, raised outlookYahoo Finance
- Moderna Stock Pops, Taps Multi-Year High After EarningsSchaeffer's Research
- Moderna Swings To A Profit And Lifts Its Revenue Outlook, But A Stock Up More Than 300% Leaves Little Room For ErrorEarnings Whispers
- Moderna shares jump as earnings beat prompts higher 2026 sales outlookProactive
- 5 Things Investors Need to Know About Fridays MarketsInvestopedia
- Moderna Shares Jump 10% as Q3 Earnings Beat Forecasts and Revenue Outlook ImprovesInvestorsHub
- Moderna Stock Is Up 700% on Cancer Vaccine Hype. Earnings Reveal That Covid Still Counts.Barrons.com
Screen Performance
Aggregate stats across all 2145 tickers our top-EPS-revision screen has flagged over the past 225 days.
- Median return since detection
- -2.9%
- % of tickers in the green
- 43%
- Median return on winners
- +22.8%
- Large revisions captured
- 2246
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Also Tracked by Our Screen
Frequently Asked Questions
Why did Moderna Inc (MRNA) stock go up recently?▾
Moderna Inc (MRNA) stock has risen following an analyst upgrade of its next-year EPS growth estimate from 43.52% to 45.53% on 2026-11-06. EPS estimate upgrades are among the strongest leading indicators of stock outperformance.
What is Moderna Inc's next-year EPS growth estimate?▾
As of 2026-11-12, Moderna Inc (MRNA) has a next-year EPS growth estimate of 43.08%, based on analyst consensus.
When was the latest EPS estimate revision for MRNA?▾
The most recent revision occurred on 2026-11-12, when analysts adjusted the next-year EPS growth estimate from 43.62% to 43.08%.
What sector and industry does Moderna Inc belong to?▾
Moderna Inc operates in the Healthcare sector, specifically the Biotechnology industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. MRNA appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. Moderna Inc (MRNA) appears here because it was detected by our daily top-EPS-revision-performer screen.